Competitor Tracker
The competitor intelligence tracker monitors key competitive products across markets and indications relevant to the KCL portfolio. Approval dates, label claims, and competitive threats are continuously updated from public sources. Linked to the intelligence and labeling modules for label harmonisation.
| ID | Competitor Product | Company | Indication | Authority | Stage | Approval Date | Competitive Threat |
|---|---|---|---|---|---|---|---|
| COMP-001 | Durvaluprim | Astarix Pharma | NSCLC — PD-L1+ | FDA | Approved | 2024-03-15 | Direct competitor in PD-L1+ NSCLC — overlapping label |
| COMP-002 | Belimabev | Novagen BV | Systemic Lupus | EMA | Approved | 2023-11-20 | Pricing competition in EU — market share risk |
| COMP-003 | Elexizumab | Hephaestos AG | RA / IBD | EMA | Under Review | Pending | Phase III results showed superiority claim — label impact |
| COMP-004 | Tasitinib | Regensol Ltd | CML | PMDA | Approved | 2024-07-08 | JP market entry — price pressure on KCL portfolio |
| COMP-005 | Frazolimab | BioPharmax Inc | Atopic Dermatitis | FDA | PDUFA Q4 2025 | Pending | Potential blockbuster — monitor PDUFA date closely |
| COMP-006 | Saridegib-2 | Celluform AG | Basal Cell Carcinoma | EMA | Approved | 2023-06-22 | Orphan overlap — shared indication footprint |